TG 1050

Drug Profile

TG 1050

Alternative Names: TG-1050

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transgene
  • Developer Transgene; Transgene - Tasly Pharmaceutics Group (JV)
  • Class Hepatitis B vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 15 Sep 2017 Transgene has patent protection for TG 1050 upto 2032
  • 16 Nov 2016 Pharmacodynamics data from a preclinical trial in Hepatitis B presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 14 Nov 2016 Preclinical data presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top